Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  thalidomide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 157 for your search:
Start Over
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: UARK 2003-26, NCT00090493
Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 19 and over
Sponsor: Other
Protocol IDs: 01-002-0601, NCT00205751
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 000080, 00-C-0080, NCI-00-C-0080, NCI-T99-0053, T99-0053, NCT00020085, NCT00004635
Phase III Randomized Study of Interferon alfa-2b With or Without Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-2898, NCT00005966, E2898
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
Phase: Phase III
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2012-02461, RTOG-BR-0118, CDR0000069268, RTOG-DEV-1006, U10CA021661, NCT00033254
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000069274, U10CA021115, E-E1A00, E1A00, NCT00033332
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2012-02475, CDR0000069441, GOG-0198, U10CA027469, NCT00041080
Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: MY10, CAN-NCIC-MY10, CAN-NCIC-JMY10, ECOG-NCIC-JMY10, CELGENE-CAN-NCIC-MY10, CDR0000258158, NCIC-MY.10, NCT00049673
Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: CDR0000302440, LLCG-STUDY-12, EU-20207, ISRCTN16174527, NCT00061919
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: THAL-MM-003, NCT00057564
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR004579, DO04-23-006, NCT00097981
Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 2005-01, NCT00111748
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 2004.00, NCI-2009-01543, FHCRC-2004.00, 6004, MEDIMMUNE-FHCRC-2004.00, NCT00217438
Thalidomide to Patients With Previously Untreated Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: NMSG #12, NFR 90000288, NCT00218855
The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: Under 60
Sponsor: Other
Protocol IDs: MM01, NCT00207805
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EudraCT: 2005-001628-35, EBMT-CLWP: 42206611, NCT00256776
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000530050, P30CA015083, MC0289, 421-03, MAYO-MC0289, MAYO-IRB-421-03, NCT00432458
GEM05 for Patients With Multiple Myeloma More Than 65 Years Old
Phase: Phase III
Type: Treatment
Status: Completed
Age: 66 and over
Sponsor: Other
Protocol IDs: 2005-001111-21, NCT00443235
Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: THA PH INT 2005 CL001, NCT00452569
GEM05 for Patients With Multiple Myeloma Under 65 Years
Phase: Phase III
Type: Treatment
Status: Completed
Age: 65 and under
Sponsor: Other
Protocol IDs: 2005-001110-41, NCT00461747
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C05009, NCT00507416
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 74
Sponsor: Other
Protocol IDs: UARK 2006-66, NCT00572169
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00522, CDR0000583984, ECOG-E1A06, E1A06, U10CA180820, U10CA021115, NCT00602641
Start Over